UBS Group’s Cartesian Growth Corp II RENE Stock Holding History

UBS Group’s Portfolio RENE Stock Details RENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-281	Closed	-$3.33K	–	10750
2025 Q1	$3.33K	Buy	+281	New	+$3.3K	﹤0.01%	9226
2024 Q4	–	Sell	-38	Closed	-$436	–	10315
2024 Q3	$436	Sell	38 -4,078	-99%	-$46.4K	﹤0.01%	8944
2024 Q2	$46.4K	Buy	4,116 +4,049	+6,043%	+$45.4K	﹤0.01%	6744
2024 Q1	$744	Hold	67	–	–	﹤0.01%	8381
2023 Q4	$734	Buy	+67	New	+$729	﹤0.01%	8531
2023 Q3	–	Sell	-99	Closed	-$1.05K	–	9877
2023 Q2	$1.05K	Sell	99 -324	-77%	-$3.43K	﹤0.01%	8022
2023 Q1	$4.44K	Buy	423 +180	+74%	+$1.87K	﹤0.01%	8191
2022 Q4	$2.49K	Buy	+243	New	+$2.46K	﹤0.01%	9668

Other funds holding RENE

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

UBS Group's RENE Position: Q2 2025 in Review

UBS Group sold out of Cartesian Growth Corp II (RENE) in Q2 2025, closing a stake of 281 shares — an estimated $3.33K sold.

UBS Group first reported a position in RENE in Q4 2022 and held it in 8 quarters. The position peaked at $46.4K in Q2 2024. 4 funds tracked by Wall St. Rank hold RENE as of Q2 2025.

UBS Group reported no remaining Cartesian Growth Corp II position as of Q2 2025 after selling out during the quarter.
UBS Group sold 281 Cartesian Growth Corp II shares in Q2 2025, an estimated $3.33K.
UBS Group first reported a position in Cartesian Growth Corp II in Q4 2022 and held it in 8 quarters.
UBS Group's Cartesian Growth Corp II position peaked at $46.4K in Q2 2024.
4 funds tracked by Wall St. Rank held Cartesian Growth Corp II as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.